Abstract 1710P
Background
Although eligibility criteria are an essential component of clinical trial design, overly restrictive criteria contribute to low accrual and poor generalizability of study results. To make trials more inclusive, there has been an increasing interest in broadening eligibility criteria, but how this affects patient safety remains unclear. In the Drug Rediscovery Protocol (DRUP, NCT02925234), protocol exceptions that were granted by the study team, taking into account the balance of potential benefits and risks, were analyzed. Here we describe the impact of these protocol waivers on patient safety and treatment efficacy.
Methods
DRUP is a Dutch multicentred, non-randomized, pan-cancer platform trial in which treatment-refractory patients are treated with targeted- and immunotherapies outside their registered indications, based on their tumor molecular profile. We collected data of all included patients for whom a waiver was granted and analyzed them in terms of treatment safety and efficacy. Also, safety and efficacy outcomes of these patients were compared to those of patients that did not need a waiver to participate.
Results
Between September 1, 2016, and September 1, 2021, 1019 patients were included in DRUP. In total, 88 protocol waivers were granted for 82 patients (8%). Most waivers were granted for general- or drug-related eligibility criteria (44%). For 32 of 82 patients that received a waiver (39%), 49 SAEs regardless of relationship to study treatment, were reported. For the included patients without a waiver (n=937), 666 SAEs were reported in 385 patients (41%, p = 0.81). The clinical benefit rate (CBR; either objective response or stable disease (SD) ≥ 16 weeks) of patients for whom a waiver was granted was 40% (14 patients (17%) with a partial response and 19 (23%) with SD ≥ 16 weeks), compared to a CBR of 33% in the non-waiver population (p = 0.43).
Conclusions
Safety and clinical benefit were preserved in patients for whom a waiver was granted in DRUP. Our data advocate omittance of ‘old’ unnecessarily strict safety criteria when setting up molecularly driven trials and support a more personalized approach in assessing eligibility criteria, especially in trials with therapeutic intent for patients without other treatment options.
Clinical trial identification
NCT02925234.
Editorial acknowledgement
Legal entity responsible for the study
The Netherlands Cancer Institute.
Funding
Stelvio for Life Foundation: funding; Dutch Cancer Society (KWF): funding; Hartwig Medical Foundation (HMF): genome sequencing; Pharmaceutical partners (Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Clovis, Eisai, Janssen, Lilly, Merck, Novartis, Pfizer, Roche): funding and study drugs.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1747P - The need for a better discussion between doctors and patients with regards to fertility preservation and vaginal rehab after anti cervical cancer treatments
Presenter: Bar Levy
Session: Poster session 23
1748P - Tackling childhood obesity epidemic on southern Europe through soft drink advertisement policies: Should oncology societies have a say?
Presenter: Konstantinos Kamposioras
Session: Poster session 23
1749P - Prevention of modifiable cancer risks in informal family caregivers of cancer patients: Implementation and evaluation of a personalised primary prevention intervention (PREV-AIDANT)
Presenter: Beatrice Fervers
Session: Poster session 23
1751P - Re-ranking cancer mortality using years of life lost
Presenter: Cecilia Radkiewicz
Session: Poster session 23
1752P - Clinical benefit of immunotherapies in advanced cancer in France: A population-based estimate from 2014 to 2021
Presenter: Isabelle Borget
Session: Poster session 23
1753P - Universal DPYD genotyping in patients with gastrointestinal malignancies: Real-world data from a single institution in Italy
Presenter: Claudia Cardone
Session: Poster session 23
1754P - Towards a next-generation sequencing/comprehensive genomic profiling value framework: Systematic review for identifying new domains and adapting a diagnostic test value framework in Europe
Presenter: Federico Augustovski
Session: Poster session 23
1755P - Carbohydrate quality index and incidence of obesity-related cancers: The Seguimiento Universidad de Navarra (SUN) project
Presenter: Maria Olmedo López-frías
Session: Poster session 23
1756P - Vizcan: A Swedish population-based study to address cancer outcomes using an interactive platform
Presenter: Anders Berglund
Session: Poster session 23